retatrutide regulatory approval Retatrutide: FDA time, trial results & weight loss Retatrutide, an experimental weight-loss drug,

95% CI, 3.14-6.09), with rates of 11.9% in GLP-1RA users vs

The TriNetX platform has been used in retrospective cohort studies [25,26,27,28,29,30,31,32,33,34,35,36,37,38] including evaluating risk and health outcomes of patients with substance use disorders including CUD [25, 32, 35] and the associations of GLP-1RAs with cancer [37] and semaglutide with suicidal ideations [38]

In contrast, Noom states that their dosing starts at 25% or less of the standard 0.25 mg dose and escalates at a personalized rate. While microdosing GLP-1 medications may provide a more personalized experience, there are still questions regarding the safety of this practice as there are currently no published studies on the process, and the microdoses may come from a compounding pharmacy

It is currently the subject of several clinical trials testing whether it can be used for overweight or obesity